Table 1.

Patient characteristics and molecular analyses of patients with PDAC included in the NCT/DKTK MASTER precision oncology program

Patient characteristics
 Patients (n)17
 Age at the time of diagnosis (median, range)39 (24–49)
 Sex (KRAS-mutated tumors/KRASWT tumors)
  Male12 (10/2)
  Female5 (3/2)
 Systemic therapies prior to inclusion (median, range)1 (0–3)
  FOLFIRINOX14
  Gemcitabine and nab-paclitaxel8
  Other2
Molecular analysis
 WES12
 WGS5
 Transcriptome sequencing15